Cargando…
Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn’s disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and Methods:...
Ejemplares similares
-
Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
por: Albshesh, Ahmad, et al.
Publicado: (2023) -
Comparative onset of effect of biologics and small molecules in moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis
por: Attauabi, Mohamed, et al.
Publicado: (2023) -
Assessment of patients' understanding of inflammatory bowel diseases: Development and validation of a questionnaire
por: Ostromohov, Gaiana, et al.
Publicado: (2021) -
Use of vedolizumab in a patient with chronic and refractory pouchitis
por: Orfanoudaki, Eleni, et al.
Publicado: (2018) -
Keeping on the High Quality of Health Care in Greek Inflammatory Bowel Disease Patients in the SARS-CoV-2 Era
por: Foteinogiannopoulou, Kalliopi, et al.
Publicado: (2020)